# BI 2536 Second Line Monotherapy in SCLC

> **NCT00412880** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 23 (actual)

## Conditions studied

- Carcinoma, Small Cell

## Interventions

- **DRUG:** BI 2536

## Key facts

- **NCT ID:** NCT00412880
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-14
- **Primary completion:** 2008-06-30
- **Final completion:** 2008-06-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412880, "BI 2536 Second Line Monotherapy in SCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00412880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*